



ALLIANCE FOR INNOVATION
ON MATERNAL HEALTH



**Care for Pregnant and Postpartum
People with Substance Use Disorder
Patient Safety Bundle**

*Core Data Collection Plan
Version 2.0
April 2022*



Care for Pregnant and Postpartum People with Substance Use Disorder Patient Safety Bundle

Core Data Collection Plan

Measurement Statement: For the purposes of quality improvement measurement and standardized data collection and reporting, AIM includes the following substances as part of its definition of SUD: opioids, amphetamines/stimulants, sedatives, and cocaine. A list of ICD-10 codes is at the end of this document.

State Surveillance

Metric	Name	Description	Notes
SS1	Substance use disorders among pregnant and postpartum people	<p>A. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages</p> <p>Numerator: Among the denominator, those with any diagnosis of substance use disorder</p> <p>B. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages</p> <p>Numerator: Among the denominator, those with a diagnosis of opioid use disorder</p>	Disaggregate by race/ethnicity
SS2	Severe Maternal Morbidity (SMM) (including transfusion codes) among people with SUD	<p>A. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with substance use disorder</p> <p>Numerator: Among the denominator, those with any SMM code</p> <p>B. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with opioid use disorder</p> <p>Numerator: Among the denominator, those with any SMM code</p>	Disaggregate by race/ethnicity

Metric	Name	Description	Notes
SS3	Severe Maternal Morbidity (SMM) (excluding transfusion codes) among people with SUD	<p>A. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with substance use disorder</p> <p>Numerator: Among the denominator, all those with any non-transfusion SMM code</p> <p>B. Denominator: All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with opioid use disorder</p> <p>Numerator: Among the denominator, those with any non-transfusion SMM code</p>	Disaggregate by race/ethnicity
SS4	Proportion of pregnancy associated deaths due to overdose	<p>A. Denominator: Total pregnancy-associated deaths</p> <p>B. Numerator: Pregnancy-associated deaths due to overdose</p>	Disaggregate by race/ethnicity

Outcome Measures

Metric	Name	Description	Notes
O1	Percent of newborns exposed to substances in utero who were discharged to either birth parent	<p>Report N/D Denominator: Newborns exposed to substances in utero Numerator: Among the denominator, those who were discharged to either birth parent</p>	<p>Disaggregate by race/ethnicity</p> <p>This outcome may also be interpreted as a balancing measure.</p>
O2	Percent of pregnant and postpartum people with OUD who received or were referred to medication for opioid use disorder (MOUD)	<p>Report N/D Denominator: Pregnant and postpartum people with a diagnosis of opioid use disorder Numerator: Among the denominator, those with documentation of having received or been referred to MOUD prior to discharge from their birth hospitalization</p> <p><i>Refer to P2 for complementary measure.</i></p>	<p>Disaggregate by race/ethnicity</p> <p>Include in the numerator:</p> <ul style="list-style-type: none"> • Those who received MOUD at any point during their pregnancy, regardless of current use • Those who did not receive MOUD during pregnancy but were referred to MOUD prior to discharge from birth hospitalization

Metric	Name	Description	Notes
O3	Percent of pregnant and postpartum people with SUD who received or were referred to recovery treatment services	<p>Report N/D</p> <p>Denominator: Pregnant and postpartum people with a diagnosis of substance use disorder, including opioid use disorder</p> <p>Numerator: Among the denominator, those with documentation of having received or been referred to recovery treatment services prior to discharge from their birth hospitalization</p> <p><i>Refer to P4 for complementary measure.</i></p>	<p>Disaggregate by race/ethnicity</p> <p>Include in the numerator:</p> <ul style="list-style-type: none"> • Those who received recovery treatment services at any point during their pregnancy, regardless of current utilization • Those who did not receive recovery treatment services during pregnancy but were referred to them prior to discharge from birth hospitalization <p>Recovery treatment services include:</p> <ul style="list-style-type: none"> • Residential treatment or inpatient recovery programs • Outpatient treatment • Behavioral health counseling • Peer support counseling, such as a 12-step program • Methadone treatment program
O4	Percent of pregnant and postpartum people with SUD who received or were prescribed Naloxone prior to delivery discharge	<p>Report N/D</p> <p>Denominator: Pregnant and postpartum people with a diagnosis of substance use disorder</p> <p>Numerator: Among the denominator, those with documentation of having received or been prescribed Naloxone prior to discharge from their birth hospitalization</p> <p><i>Refer to P4 for complementary measure.</i></p>	Disaggregate by race/ethnicity

Process Measures

Metric	Name	Description	Notes
P1	Percent of pregnant and postpartum people screened for SUDs	<p>Sample patient charts or report for all patients; report N/D</p> <p>Denominator: Pregnant and postpartum people during their birth hospitalization</p> <p>Numerator: Among the denominator, those with documentation of having been screened for substance use disorder using a validated verbal screening tool during their birth hospitalization</p>	Disaggregate by race/ethnicity
P2	Percent of pregnant and postpartum people with OUD who were counseled on medication for opioid use disorder (MOUD)	<p>Report N/D</p> <p>Denominator: Pregnant and postpartum people with a diagnosis of opioid use disorder during their birth hospitalization</p> <p>Numerator: Among the denominator, those with documentation of counseling for MOUD prenatally or during their birth hospitalization</p> <p><i>Refer to O2 for complementary measure</i></p>	Disaggregate by race/ethnicity
P3	Percent of pregnant and postpartum people with SUD who were counseled on recovery treatment services	<p>Report N/D</p> <p>Denominator: Pregnant and postpartum people with a diagnosis of substance use disorder, including opioid use disorder during their birth hospitalization</p> <p>Numerator: Among the denominator, those with documentation of counseling for recovery treatment services prenatally or during their birth hospitalization</p> <p><i>Refer to O3 for complementary measure</i></p>	<p>Disaggregate by race/ethnicity</p> <p>Recovery treatment services include:</p> <ul style="list-style-type: none"> • Residential treatment or inpatient recovery programs • Outpatient treatment • Behavioral health counseling • Peer support counseling, such as a 12-step program • Methadone treatment program

Metric	Name	Description	Notes
P4	Percent of pregnant and postpartum people with SUD who received Naloxone counseling	<p>Report N/D</p> <p>Denominator: Pregnant and postpartum people with a diagnosis of substance use disorder during their birth hospitalization</p> <p>Numerator: Among the denominator, those with documentation of counseling for Naloxone prenatally or during their birth admission</p> <p><i>Refer to O4 for complementary measure</i></p>	Disaggregate by race/ethnicity
P5	Provider and Nursing Education – Substance Use Disorders	<p>Report proportion completed (estimated in 10% increments – round up)</p> <p>At the end of this reporting period, what cumulative proportion of OB providers and nurses (including L&D and PP) has received within the last 2 years an education program on care for pregnant and postpartum people with substance use disorders?</p>	
P6	Provider and Nursing Education – Respectful and Equitable Care	<p>Report proportion completed (estimated in 10% increments-round up)</p> <p>At the end of this reporting period, what cumulative proportion of inpatient clinical OB providers and nursing staff has received within the last two years an education program on respectful and equitable care?</p>	

Structure

Metric	Name	Description	Notes
S1	Resource Mapping/ Identification of Community Resources	<p>Report Initial Completion Date Has your hospital created a comprehensive list of community resources, customized to include resources relevant for pregnant and postpartum people, that will be shared with all postpartum inpatient nursing units and outpatient OB sites?</p>	<ul style="list-style-type: none"> • Resource list should be updated annually. • Resource list should include OUD/SUD treatment resources as well as mental health resources and allow for customization based on patient population (e.g., BIPOC).
S2	Patient Event Debriefs	<p>Report Start Date Has your department established a standardized process to conduct debriefs with patients after a severe event?</p>	<ul style="list-style-type: none"> • Include patient support networks during patient event debriefs, as requested. • Severe events may include the TJC sentinel event definition, severe maternal morbidity, or fetal death.
S3	General Pain Management Guidelines	<p>Report Completion Date Has your hospital implemented post-delivery and discharge pain management prescribing guidelines for routine vaginal and cesarean births focused on limiting opioid prescriptions?</p>	
S4	OUD Pain Management Guidelines	<p>Report Completion Date Has your hospital implemented specific pain management and opioid prescribing guidelines for patients with a diagnosis of opioid use disorder?</p>	

S5	Validated Verbal Screening Tools and Resources Shared with Prenatal Care Sites	Report Completion Date Has your hospital shared with all its prenatal care sites validated verbal screening and follow up tools for diagnosis of opioid use and substance use disorders?	Follow up tools include Screening, Brief Intervention and Referral to Treatment (SBIRT) resources.
----	--	---	--

AIM Data SUD Codes List

Substance	Definition
Opioids	F1110, F1111, F11120, F11121, F11122, F11129, F1114, F11150, F11151, F11159, F11181, F11182, F11188, F1119, F1120, F1121, F11220, F11221, F11222, F11229, F1123, F1124, F11250, F11251, F11259, F11281, F11282, F11288, F1129, F1190, F11920, F11921, F11922, F11929, F1193, F1194, F11950, F11951, F11959, F11981, F11982, F11988, F1199
Sedatives	F1310, F1311, F13120, F13121, F13129, F1314, F13150, F13151, F13159, F13180, F13181, F13182, F13188, F1319, F1320, F1321, F13220, F13221, F13229, F13230, F13231, F13232, F13239, F1324, F13250, F13251, F13259, F1326, F1327, F13280, F13281, F13282, F13288, F1329, F1390, F13920, F13921, F13929, F13930, F13931, F13932, F13939, F1394, F13950, F13951, F13959, F1396, F1397, F13980, F13981, F13982, F13988, F1399
Cocaine	F1410, F1411, F14120, F14121, F14122, F14129, F1414, F14150, F14151, F14159, F14180, F14181, F14182, F14188, F1419, F1420, F1421, F14220, F14221, F14222, F14229, F1423, F1424, F14250, F14251, F14259, F14280, F14281, F14282, F14288, F1429, F1490, F14920, F14921, F14922, F14929, F1494, F14950, F14951, F14959, F14980, F14981, F14982, F14988, F1499
Amphetamines/Stimulants	F1510, F1511, F15120, F15121, F15122, F15129, F1514, F15150, F15151, F15159, F15180, F15181, F15182, F15188, F1519, F1520, F1521, F15220, F15221, F15222, F15229, F1523, F1524, F15250, F15251, F15259, F15280, F15281, F15282, F15288, F1529, F1590, F15920, F15921, F15922, F15929, F1593, F1594, F15950, F15951, F15959, F15980, F15981, F15982, F15988, F1599

These materials were developed with support from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a cooperative agreement with the American College of Obstetricians and Gynecologists under grant number UC4MC28042, Alliance for Innovation on Maternal Health. The contents do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](https://www.hrsa.gov).

© 2022 American College of Obstetricians and Gynecologists. Permission is hereby granted for duplication and distribution of this document, in its entirety and without modification, for solely non-commercial activities that are for educational, quality improvement, and patient safety purposes. All other uses require written permission from ACOG.